Consistent with this notion, we also found that treating TAC-operated WT mice with PRGL493 (Supplementary Fig. 7) and pioglitazone (Supplementary Fig. 8), two potent and selective inhibitors of Acsl4, partially protected against cardiac hypertrophy, reduced the expression of cardiac hypertrophy markers, and improved ventricular function. The gene discussed is ACSL4; the disease is cardiac hypertrophy.